enVVeno Medical Corp
NASDAQ:NVNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
United Faith Auto Engineering Co Ltd
SZSE:301112
|
CN |
|
L E Lundbergforetagen AB (publ)
STO:LUND B
|
SE |
|
INKON Life Technology Co Ltd
SZSE:300143
|
CN |
enVVeno Medical Corp
Total Equity
enVVeno Medical Corp
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
enVVeno Medical Corp
NASDAQ:NVNO
|
Total Equity
$27.1m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Equity
$24.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
14%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Total Equity
$10.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Equity
$22.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Equity
$52.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Equity
$17.8B
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
enVVeno Medical Corp
Glance View
enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 24 full-time employees. The company went IPO on 2018-05-31. The firm is focused on improving the standard of care in the treatment of venous disease. The firm is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.
See Also
What is enVVeno Medical Corp's Total Equity?
Total Equity
27.1m
USD
Based on the financial report for Dec 31, 2025, enVVeno Medical Corp's Total Equity amounts to 27.1m USD.
What is enVVeno Medical Corp's Total Equity growth rate?
Total Equity CAGR 5Y
31%
Over the last year, the Total Equity growth was -36%. The average annual Total Equity growth rates for enVVeno Medical Corp have been -11% over the past three years , 31% over the past five years .
